Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind tolebrutinib trial in generalized myasthenia gravis (Japan)
jRCT2031220158Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing tolebrutinib with placebo/tolebrutinib (2 arms). Primary endpoints: Change from baseline in MG-ADL total score (double-blind period) and Number of participants with AEs/SAEs (open-label extension). Started Jul 2022; status: completed.
02
Drugs
tolebrutinib
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCT2031220158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220158.